Jefferson University Hospitals

Physician Profile

Serge Jabbour, MD, FACP, FACE

Jefferson University Physician

Academic Title: Professor
Division Director, Endocrinology
Director, Diabetes Center
Director, Comprehensive Weight Management Program

Specialties
Endocrinology/Diabetes & Metabolism
Endocrinology/Diabetes & Metabolism - Thyroid & Parathyroid
Endocrinology/Diabetes & Metabolism - Weight Management

Appointment Scheduling

Call 1-800-JEFF-NOW

Existing Patients

Jefferson Health MyChart

Log in to MyChart and schedule an appointment online.

New Patients  | Online Scheduling

New patients can use Online Scheduling to view available appointment times and schedule directly.

More Ways to Get in Touch

Call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
Walnut Towers, Suite 600
211 S. 9th Street
Philadelphia PA 19107
Phone: (215) 955-1925
Fax: (215) 928-3160

Medical Services

Years in Practice

18

Board Certifications

  • Internal Medicine
  • Endocrinology, Diabetes & Metabolism

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011

Education

  • St. Joseph's University, Beirut, Lebanon, Medical School

Internship

  • Cooper Medical Center, Camden, NJ

Residency

  • Cooper Medical Center, Camden, NJ

Fellowship

  • Thomas Jefferson University Hospital

Recent Publications

Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial

Durability of response to dapagliflozin: a review of long-term efficacy and safety

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)

Diagnosis and management of thyroid lymphoma

Evaluation and management of medullary thyroid cancer

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Insulin degludec 200 Units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 Units/mL in patients with type 2 diabetes requiring high-dose insulin

Musculoskeletal manifestations of primary hyperparathyroidism

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

SGLT2 inhibitors

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study

Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Incidence and Severity of Pancreatogenic Diabetes After Pancreatic Resection

Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem

Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?

Collaboration designed to increase translation of diabetes research outcomes into clinical practice

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor Dapagliflozin